These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia. Khan MY; Kinsara AJ; Osoba AO; Wali S; Samman Y; Memish Z Int J Antimicrob Agents; 2001 May; 17(5):415-8. PubMed ID: 11337231 [TBL] [Abstract][Full Text] [Related]
3. Prediction of drug resistance by Sanger sequencing of Mycobacterium tuberculosis complex strains isolated from multidrug resistant tuberculosis suspect patients in Ethiopia. Mesfin EA; Merker M; Beyene D; Tesfaye A; Shuaib YA; Addise D; Tessema B; Niemann S PLoS One; 2022; 17(8):e0271508. PubMed ID: 35930613 [TBL] [Abstract][Full Text] [Related]
4. Treatment duration for patients with drug-resistant tuberculosis, United States. Winston CA; Mitruka K Emerg Infect Dis; 2012 Jul; 18(7):1201-2. PubMed ID: 22709909 [No Abstract] [Full Text] [Related]
5. Detection of and treatment protocol for rifampicin-monoresistant tuberculosis: what is the role of isoniazid? Velayati AA; Farnia P; Masjedi MR; Hoffner S Int J Tuberc Lung Dis; 2013 Jun; 17(6):849-50. PubMed ID: 23676176 [No Abstract] [Full Text] [Related]
6. Epidemiology of drug-resistant tuberculosis in New Jersey from 1991 to 1995. Liu Z; Shilkret KL; Finelli L Int J Epidemiol; 1998 Feb; 27(1):121-6. PubMed ID: 9563705 [TBL] [Abstract][Full Text] [Related]
7. Tuberculosis drug resistance in Canakkale, Turkey. Gonlugur T; Basol G; Gonlugur U Cent Eur J Public Health; 2020 Sep; 28(3):245. PubMed ID: 32997482 [No Abstract] [Full Text] [Related]
8. Rationale for chemotherapy of tuberculosis and current recommendations. Kumar L Indian Pediatr; 1992 Nov; 29(11):1337-9. PubMed ID: 1294486 [No Abstract] [Full Text] [Related]
9. Resistance patterns of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Nairobi. Ndung'u PW; Kariuki S; Ng'ang'a Z; Revathi G J Infect Dev Ctries; 2012 Jan; 6(1):33-9. PubMed ID: 22240426 [TBL] [Abstract][Full Text] [Related]
10. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017. Glasauer S; Altmann D; Hauer B; Brodhun B; Haas W; Perumal N PLoS One; 2019; 14(6):e0217597. PubMed ID: 31188848 [TBL] [Abstract][Full Text] [Related]
11. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Nolan CM; Goldberg SV Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140 [TBL] [Abstract][Full Text] [Related]
12. Treatment of tuberculosis. The Mitchell lecture 1979. Mitchison DA J R Coll Physicians Lond; 1980 Apr; 14(2):91-5, 98-9. PubMed ID: 6767845 [No Abstract] [Full Text] [Related]
13. Transmissibility and potential for disease progression of drug resistant Becerra MC; Huang CC; Lecca L; Bayona J; Contreras C; Calderon R; Yataco R; Galea J; Zhang Z; Atwood S; Cohen T; Mitnick CD; Farmer P; Murray M BMJ; 2019 Oct; 367():l5894. PubMed ID: 31649017 [TBL] [Abstract][Full Text] [Related]
15. High prevalence of multidrug-resistant tuberculosis in Zunyi, Guizhou Province of China. Chen L; Li N; Liu M; Zhang J; Zhang H J Antimicrob Chemother; 2011 Oct; 66(10):2435-7. PubMed ID: 21795258 [No Abstract] [Full Text] [Related]
16. [Epidural abscess due to a Mycobacterium tuberculosis strain with primary resistance to isoniazid and ethambutol]. Sener A; Akçalı A; Karatağ O; Koşar S; Değirmenci Y; Akman T Mikrobiyol Bul; 2012 Oct; 46(4):689-94. PubMed ID: 23188583 [TBL] [Abstract][Full Text] [Related]
17. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570 [TBL] [Abstract][Full Text] [Related]
18. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis. Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116 [TBL] [Abstract][Full Text] [Related]
20. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens. Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]